TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04070053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraPPP Pathway
Description: TheraPPP Steps:~Step 1. All mechanically ventilated patients will have a height measured and documented. Step 2. Screening for HRF. Step 3. Initiate Lung Protective Ventilation (LPV). Step 4. Paralysis. Step 5. Prone Positioning.
Study: NCT02755532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0,25%
Description: Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==\>140.1 m/z. The methodology was validated according to the international FDA recommendations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0,5%
Description: Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==\>140.1 m/z. The methodology was validated according to the international FDA recommendations.
Study: NCT02117206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine (L-arginine Veyron)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nacl
Study: NCT01876433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03450980

Intervention type: OTHER
Group type: OTHER
Intervention: EyeTurn App
Description: App software which analyzes the position of ocular surface reflections in a photograph to quantify eye misalignment (strabismus)
Study: NCT02092038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: partial brain irradiation
Description: Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stereotactic biopsy of brain tumor
Description: will be assessed for tumor type and tumor markers
Study: NCT01721785

Intervention type: DRUG
Intervention: GADOFOSVESET TRISODIUM 244 Mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ablavar]
Description: Gadofosveset will be used as a lymph-node specific MRI contrast agent and will be administered by manual injection as a single intravenous bolus during MRI.
Study: NCT01954615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Groups A to F)
Study: NCT02073266

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macular hole surgery using a 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macular hole surgery using a 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8.
Study: NCT02924415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-care support
Description: Psychoeducation treatment based on telemedicine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Standard care
Study: NCT00636987

Intervention type: DEVICE
Group type: OTHER
Intervention: Biocor and Biocor Supra valves
Description: Replacement for a diseased, damaged, malformed aortic or mitral heart valve
Study: NCT04306679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animation clips
Description: The first animation clip focuses on the importance of pain assessment introduce three pain scales (categorical, NPS and faces) followed by explanations on their properties and on the appropriate way to use them.The second movie was aimed to provide an opportunity to implement the new knowledge in case studies

Intervention type: OTHER
Group type: OTHER
Intervention: Instructions
Description: Routine preoperative preparations, which included a section on pain assessment instructions.
Study: NCT00704665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relaxin
Description: 10 ug/kg/day or 25 ug/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Relaxin
Description: Placebo
Study: NCT02092038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: craniotomy and tumor resection
Description: maximal safe resection
Study: NCT03443323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organizational Skills Training - Tier 2 (OST-T2)
Description: OST-T2 is a small group skills training intervention, with parents and teachers supporting children's use of new skills. The program manual includes strategies for training and coaching school staff, referred to as school partners, to effectively implement OST-T2 and guidelines to modify the program for implementation in diverse schools with diverse students. Each student session includes: (a) homework review to assess completion of between-session skills implementation; (b) skill-building activities, which include the use of modeling, shaping, guided practice, and reinforcement for organized behavior; and (c) activities to promote generalization of skills. Sessions address four organizational challenges: (a) tracking assignments, (b) managing materials, (c) managing time, and (d) planning for long term assignments.
Study: NCT01954615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Groups A to F)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Groups A to F)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Groups A to F)
Study: NCT02880501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: proximal femoral nail antirotation
Description: Twenty patients with intertrochanteric femoral fracture scheduled to undergo proximal femoral nail antirotation (PFNA) implantation.
Study: NCT01051284

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cyberknife radiation and gemcitabine
Description: 25 Gray of radiation will be given in 5 fractions using the Cyberknife Gemcitabine 1000 mg/m2 intravenously will be given once a week on days 1, 8, and 15 of every 28-day cycle for 6 cycles
Study: NCT02712775

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT00629083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bulkamid
Description: Bulking injection with Bulkamid injection device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contigen
Description: Transurethral bulking injection
Study: NCT00534534

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repeated behavioural intervention without any drugs
Description: All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion as those in the standard group. No drugs will be used as part of the intervention. They also will undergo repeated interventions at outpatient visits at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
Study: NCT03104582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP Drainage
Description: When advanced Klatskin Tumor patients need biliary drainage, they choose to perform endoscopic drainage after informed consent.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PTBD Drainage
Description: When advanced Klatskin Tumor patients need biliary drainage, they choose to perform percutaneous transhepatic biliary drainage after informed consent.
Study: NCT01482702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss intervention
Description: Behavioral weight loss intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Behavioral weight loss intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss
Description: Behavioral weight loss intervention
Study: NCT03124043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Livongo for Diabetes program
Description: See description in arm/group description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Livongo for Diabetes program
Description: See description in arm/group description.
Study: NCT02970773

Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban Oral Tablet
Description: oral application of Xarelto
Study: NCT02226354

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ahiflower oil
Description: 9.73 ml per day for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed oil
Description: 9.73ml per day for 28 days
Study: NCT01883141

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrophysiological Study
Description: Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots
Study: NCT03808961

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Niacin
Description: 100mg tablets twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Niacinamide
Description: 100mg tablets twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily
Study: NCT03834948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-176
Description: Humanized monoclonal antibody (mAb) targeting CD47

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-176
Description: Humanized monoclonal antibody (mAb) targeting CD47

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-176 + Paclitaxel
Description: Humanized monoclonal antibody (mAb) targeting CD47 and paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-176 + Paclitaxel
Description: Humanized monoclonal antibody (mAb) targeting CD47 and paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-176 + Pembrolizumab
Description: Humanized monoclonal antibody (mAb) targeting CD47 and pembrolizumab
Study: NCT02696187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KOLwebben
Description: KOL-webben will be introduced to all people with COPD during their ordinary visits to the primary care center during a 3 months period. The introduction to KOL-webben will be tailored to each person's needs and include 1) registration of the patient at KOL-webben 2) showing and discussing specific content on KOL-webben (e.g. movies with exercises if the person needs exercise training) chosen to meet the needs of the individual 3) giving a card (A5 format) with address to KOL-webben, user information and references to chosen content on KOL-webben. All patients will also receive a pedometer.
Study: NCT04195126

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb haemadsorption device
Description: CytoSorb (Cytosorbents Inc.) aspecific blood purification device used in an extracorporeal circulation system without dialysis column. Anticoagulation is managed by siodium citrate-Calcium system, using the Gambro CVVHDF capable device.
Study: NCT02551627

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test Product
Description: MMN fortified beverage powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Isocaloric beverage powder without micronutrient fortification.
Study: NCT01285687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Sterile, disposable, FDA-approved acupuncture needles will be used. Acupuncture will be performed bilaterally. The needles will penetrate the skin to a depth of 5-10mm and will be kept in place for no more than 5 minutes. The acupuncture points will be: Li 4, Li 11, St 44, according to Chinese acupuncture mapping. Treatment will be repeated at least 3 times during the hospital stay. Treatment will start in the pediatrics department approximately two hours after discharge from the postoperative unit. The 2nd treatment will be given on the same evening, approximately 4-8 hours after the 1st treatment and the 3rd treatment will be given the following morning, approximately 12-18 hours after the 2nd treatment. Exact treatment times will be recorded in the patient's file.
Study: NCT03044639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Emulsions, Intravenous
Description: The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Emulsions, Intravenous
Description: The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Emulsions, Intravenous
Description: The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Emulsions, Intravenous
Description: The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
Study: NCT04920227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification;
Description: Group A: class combined with phacoemulsification
Study: NCT02329366

Intervention type: OTHER
Intervention: Specimen Collection
Description: . In this study, diabetic patients undergoing DFU debridement under the standard of care will be asked for their permission to collect the debrided tissue for use in scientific research.

Intervention type: OTHER
Intervention: Specimen Collection
Description: . In this study, diabetic patients undergoing DFU debridement under the standard of care will be asked for their permission to collect the debrided tissue for use in scientific research.
Study: NCT03834948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-176 + Pembrolizumab
Description: Humanized monoclonal antibody (mAb) targeting CD47 and pembrolizumab
Study: NCT04874272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chaplain led post-code debrief
Description: an emotional debrief (a discussion to process the emotional, existential impact of a medical code/cardiopulmonary arrest), which will be led by a chaplain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chaplain led post-code debrief
Description: an emotional debrief (a discussion to process the emotional, existential impact of a medical code/cardiopulmonary arrest), which will be led by a chaplain
Study: NCT01649479

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Antiphospholipid antibody tests
Description: Each patient will be tested for antiphospholipid antibodies.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Antiphospholipid antibody tests
Description: Each patient will be tested for antiphospholipid antibodies.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Antiphospholipid antibody tests
Description: Each patient will be tested for antiphospholipid antibodies.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Thrombophilia bloodwork
Description: Bloodwork will be drawn up for:~* antithrombin, protein C, protein S~* Factor V Leiden polymorphisms (F5 1691A)~* prothrombin 20210A gene polymorphism (F2 20210A)~* JAK2 617F Mutation~* Homocysteine~* Factor VIII

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Thrombophilia bloodwork
Description: Bloodwork will be drawn up for:~* antithrombin, protein C, protein S~* Factor V Leiden polymorphisms (F5 1691A)~* prothrombin 20210A gene polymorphism (F2 20210A)~* JAK2 617F Mutation~* Homocysteine~* Factor VIII

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Thrombophilia bloodwork
Description: Bloodwork will be drawn up for:~* antithrombin, protein C, protein S~* Factor V Leiden polymorphisms (F5 1691A)~* prothrombin 20210A gene polymorphism (F2 20210A)~* JAK2 617F Mutation~* Homocysteine~* Factor VIII

Intervention type: OTHER
Group type: OTHER
Intervention: Psychiatric evaluation
Description: During this consultation, the Mini International Neuropsychiatric Interview will be used to screen for psychiatric symptoms. Should the latter be detected, a further consult with a psychiatrist or a psychologist will be organized; this second consult will include the Mood Disorder Questionnaire (MDQ), the Beck Depression Inventory (BDI), the Inventory for Depressive Symptomatology - Clinician (IDS-C) and the Structured Clinical Interview for Disorders (SCID, DSM-IV).
Study: NCT00710190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rheos Baroreflex Hypertension Therapy System
Description: This therapy uses implantable device-based electrical activation of the carotid sinus baroreflex to control blood pressure.
Study: NCT01794780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA based treatment: indacaterol
Description: LABA based treatment: indacaterol
Study: NCT01649479

Intervention type: OTHER
Group type: OTHER
Intervention: Psychiatric evaluation
Description: During this consultation, the Mini International Neuropsychiatric Interview will be used to screen for psychiatric symptoms. Should the latter be detected, a further consult with a psychiatrist or a psychologist will be organized; this second consult will include the Mood Disorder Questionnaire (MDQ), the Beck Depression Inventory (BDI), the Inventory for Depressive Symptomatology - Clinician (IDS-C) and the Structured Clinical Interview for Disorders (SCID, DSM-IV).

Intervention type: OTHER
Group type: OTHER
Intervention: Psychiatric evaluation
Description: During this consultation, the Mini International Neuropsychiatric Interview will be used to screen for psychiatric symptoms. Should the latter be detected, a further consult with a psychiatrist or a psychologist will be organized; this second consult will include the Mood Disorder Questionnaire (MDQ), the Beck Depression Inventory (BDI), the Inventory for Depressive Symptomatology - Clinician (IDS-C) and the Structured Clinical Interview for Disorders (SCID, DSM-IV).
Study: NCT03103815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivita
Description: In each course, Amivita solution (500ml) will be administrated i.v. once daily for 4 weeks. After an interval of 2 weeks, the participants will be treated again. A total of 7 courses will be given,
Study: NCT05052281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers and Babies (MB) Course
Description: The Mothers and Babies course (MB) is a 12-session manualized stress-reduction intervention that will be delivered to participants, prenatally, with an integrated technology suite designed for timely detection and response to maternal stress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just in Time Intervention (JITI) Content
Description: Participants will also receive additional MB intervention content in the form of just-in-time text messages, which will be sent to participants' smartphones every other day for up to 12 weeks. During the current trial, participants will receive text message prompts with links to additional stress reduction content based on a combination of their objective (sensor) and subjective (EMA) stress responses from the previous day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biostamp nPoint Device
Description: During the intervention period, participants will be asked to wear the BioStamp nPoint sensor, daily, while engaging in their usual activities (e.g., sleep, showering, exercise). The BioStamp Sensor is a thin, wearable patch, equipped with wireless high-range 6-axis gyroscope + accelerometer, and sEMG and ECG sensors, that adheres to the skin using a disposable medical-grade adhesive sticker (with adhesive similar to Band-Aid).
Study: NCT01479491

Intervention type: OTHER
Intervention: Data collection
Description: Data source will be the Japan Medical Data Centre Company Limited (JMDC) - JMDC Medical Data Bank (JMDC-MDB) database. Aggregated data (age in months and years and gender) for all subjects recorded in the database and subject-level data for IS cases will be extracted from the database. This database will be reviewed to extract data for the period between January 2005 and April 2011. Cases of IS will be identified using the International Classification of Diseases-10 (ICD-10) diagnostic codes, examination codes and procedural codes.
Study: NCT05052281

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biostamp nPoint Device
Description: During the intervention period, participants will be asked to wear the BioStamp nPoint sensor, daily, while engaging in their usual activities (e.g., sleep, showering, exercise). The BioStamp Sensor is a thin, wearable patch, equipped with wireless high-range 6-axis gyroscope + accelerometer, and sEMG and ECG sensors, that adheres to the skin using a disposable medical-grade adhesive sticker (with adhesive similar to Band-Aid).
Study: NCT02852083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 25 mg once daily, p.o.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nivolumab
Description: 3 mg per kilogram of body weight every 2 weeks, p.o. (standard treatment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Treosulfan 250 mg twice daily, p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 250 mg twice daily p.o.
Study: NCT01010100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose (Glucobay, BAYG5421)
Description: 50 mg TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg TID